Maura N. Dickler, MD

Dr. Dickler on MONARCH 1 Results in HR+/HER2- Breast Cancer

June 7th 2016

Maura N. Dickler, MD, Memorial Sloan Kettering Cancer Center, discusses the results of the single-arm MONARCH 1 trial, which examined the efficacy of the CDK4/6 inhibitor abemaciclib in heavily pretreated patients with refractory, hormone-receptor (HR)–positive, HER2-negative advanced breast cancer.